

KYOWA KIRIN

News Release

Transfer of BioWa’s “External Innovation Engine” In-Licensing Activities to Kyowa Hakko Kirin California

La Jolla, CA, February 16, 2015 -- Kyowa Hakko Kirin California, Inc. (President: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "KKC"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & CEO: Nobuo Hanai, Ph.D.; headquartered in Tokyo, Japan: "Kyowa Hakko Kirin"), announced today the transfer of in-licensing activities of its sister company, BioWa, Inc. (President and CEO: Yasunori Yamaguchi, Ph.D. headquartered in La Jolla, California; "BioWa"), which is also a wholly owned subsidiary of Kyowa Hakko Kirin, to KKC.

With this business transition, KKC takes over BioWa’s in-licensing activities also known as "External Innovation Engine (EIE)". KKC will serve as an oversea window for the Research and Development Division of Kyowa Hakko Kirin and actively seek external opportunities in products at discovery through pre-clinical stages and in novel innovative technologies to enrich Kyowa Hakko Kirin's research product pipeline in the areas of oncology, immunology (inflammations, autoimmune diseases), nephrology and central nervous system. KKC will also consider strategic collaborations and/or partnerships with pharmaceuticals, biotech and academia.

“By transferring the EIE function to KKC, we can work more directly and efficiently with the Open Innovation Department under the Research and Development Division of Kyowa Hakko Kirin to accelerate its external innovation activities.”, said Yasunori Yamaguchi Ph.D., President of KKC. “Furthermore, we can also utilize the lab activities of KKC to focus on exploratory and translational research for external opportunities.”

As a subsidiary of Kyowa Hakko Kirin, KKC will contribute to healthy, fulfilling, and comfortable lives for all.

Contact:

Kyowa Hakko Kirin California, Inc.
9420 Athena Circle
La Jolla, CA 92037
858-952-7000
info@kyowa-kirin-ca.com
<http://kyowa-kirin.com/kkc>